Pediatric cancer recurrence, particularly in the context of gliomas, poses a significant challenge in the field of pediatric oncology.Recent advancements, like an AI tool designed to improve glioma risk assessment, have demonstrated an ability to predict relapse risk with remarkable accuracy.